Soleno Therapeutics (SLNO) Stock Jumps 30% on Neurocrine $2.5B Buyout Report

TLDR

• Soleno Therapeutics (SLNO) surged over 30% in premarket trading Monday after reports of a buyout deal
• Neurocrine Biosciences (NBIX) is in advanced talks to acquire Soleno for $2.5B or more
• The deal could value SLNO in the low-to-mid $50s per share
• A deal could be finalised as soon as Monday, April 6, per the Financial Times
• Neurocrine fell 0.4% in premarket on the news

Soleno Therapeutics has had a rough 2026 — down around 14% year to date — but that changed fast on Monday morning.

Soleno Therapeutics, Inc., SLNO

The Financial Times reported that Neurocrine Biosciences is in advanced talks to buy the rare disease biotech in a deal worth more than $2.5 billion. The report sent SLNO surging over 30% in premarket trading.

The deal would value Soleno in the low-to-mid $50s per share. Discussions are moving quickly, and the FT said a deal could be agreed as soon as Monday.

Soleno’s core asset is Vykat XR, a drug it launched last year to treat hyperphagia — a condition linked to Prader-Willi syndrome. Hyperphagia causes extreme, persistent hunger that can lead to serious complications including stomach rupture, choking, obesity, and cardiovascular disease.

Prader-Willi syndrome is a rare genetic disorder, occurring in roughly one in every 15,000 live births. Vykat XR is the first commercialised drug approved to treat the hunger-related symptoms of the condition.

Analysts have forecast peak annual sales of up to $2.3 billion for Vykat XR — a number that clearly caught Neurocrine’s attention.

Neurocrine Moves Into Rare Disease

Neurocrine currently carries a market cap of around $13.21 billion. Its portfolio includes Ingrezza, which treats involuntary movements tied to Huntington’s disease, along with several other approved drugs and a pipeline of candidates.

Adding Vykat XR would give Neurocrine a foothold in the rare disease and orphan drug space, where pricing power tends to be strong and competition limited.

Neurocrine’s stock dipped 0.4% in premarket trading Monday. That’s a fairly typical reaction when a buyer enters an acquisition — investors price in the premium being paid.

SLNO’s Run-Up in Context

Even with Monday’s spike, SLNO was down around 14% in 2026 heading into this week. The stock had struggled despite analyst optimism around Vykat XR’s commercial potential.

On TipRanks, SLNO holds a Strong Buy consensus from 11 analysts. The average price target sits at $101.09, with the highest at $125.

At the reported deal price of low-to-mid $50s per share, the acquisition would come in well below those analyst targets — though it would represent a substantial premium to where SLNO had been trading recently.

The Financial Times report cited sources familiar with the matter, noting discussions are progressing well and moving rapidly toward a potential agreement.

The post Soleno Therapeutics (SLNO) Stock Jumps 30% on Neurocrine $2.5B Buyout Report appeared first on CoinCentral.